Sun L, Cohen RB, D'Avella CA, Singh AP, Schoenfeld JD, Hanna GJ. Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC , JAMA Netw Open, 7: 2024,e2428526
Christopher D'Avella, Meredith Doherty, E. Paul Wileyto, Jason Ma, Suzanne Walker, Jessica Jacoby, Chelsea Brown, Chiu Yi Tan, Tamara Cadet Financial toxicity screening in an urban underserved patient population with cancer , ASCO Quality Symposium: 2024
Shannon Ugarte, Christopher D'Avella, Peter Edward Gabriel, Christine Agnes Ciunci, Megan Roy, Amy Schwartz, Katie Boyk, Suzanne Walker, Jessica Tindall, and David W. Dougherty The cancer diagnostic clinic: A rapid access clinic to improve outcomes for patients with a suspected cancer diagnosis , ASCO Quality Care Symposium Meeting: 2024
Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation , Clin Lung Cancer: 2024
Meredith Doherty, Kellie Bresz, Kimberly Guglielmo, Christopher Davella, Tamara Cadet, Suzanne Walker, Paul Wileyto Does financial advocacy improve appointment keeping in patients receiving chemotherapy? , ASCO Quality Care Symposium: 2023
Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression , Clin Lung Cancer: 2023
Aggarwal C, Maity AP, Bauml JM, Long Q, Aleman T, Ciunci C, D'Avella C, Volpe M, Anderson E, Jones LM, Sun L, Singh AP, Marmarelis ME, Cohen RB, Langer CJ, Amaravadi R. A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer , Oncologist, 28: 2023,644-e564
Christopher Davella, Erin Mary Bange, Aditi Puri Singh, David W. Dougherty, Peter Edward Gabriel, Rebecca Lawrence Maniago, Jennifer Miao, Colin Harvey, Marcello Ricottone, Lawrence N. Shulman Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health. , ASCO Annual Meeting: 2023
Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System , Clin Lung Cancer: 2023
Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME. Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens , Clin Lung Cancer: 2023
